Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients

C. Clemente, F. Belli, L. Mascheroni, R. Bufalino, S. Rao, M. T. Baldini, M. C. Mihm, N. Cascinelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Eight patients with cutaneous metastatic melanoma were submitted to high-dose intravenous thymopentin (TP5) treatment for 5 weeks: three patients received 1 g three times a week, three received 1 g daily and two received 2 g daily. Four out of eight patients presented a partial response of cutaneous lesions lasting for 1-7 months, and six remain alive with evidence of disease after a follow-up of 2-7 months. A remarkable histologic observation is the presence of tumour necrosis, which was seen as both single cells and large confluent areas. The majority of lymphold cells present in the tumour are CD45RO+ and CD4+. The CD4+ cells might play an important role in the anti-tumour immune local response by secreting cytokines and inducing apoptotic and necrotic cell death. This hypothesis seems to be confirmed by the presence of a high number of CD4+ cells around intratumoral vessels, while the presence of endovascular micro-thrombosis provides indirect evidence of cytokine activity. Cellular lysis may be produced by the activity of both CD8+ and CD4+ lymphoid cells. The role of TP5 may be an activation of CD4+ and CD8+ lymphold cells. Clinical and pathological data indicate that TP5 is able to produce consistent clinical and immunological effects in melanoma patients with cutaneous metastases.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalMelanoma Research
Volume6
Issue number1
Publication statusPublished - 1996

Fingerprint

Thymopentin
Melanoma
Skin
Cytokines
Neoplasms
Thrombosis
Cell Death
Necrosis
Cell Count
Observation
Lymphocytes
Neoplasm Metastasis

Keywords

  • Immunomodulator
  • Melanoma
  • Thymopentin
  • TIL
  • TP5

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this

Clemente, C., Belli, F., Mascheroni, L., Bufalino, R., Rao, S., Baldini, M. T., ... Cascinelli, N. (1996). Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. Melanoma Research, 6(1), 63-69.

Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. / Clemente, C.; Belli, F.; Mascheroni, L.; Bufalino, R.; Rao, S.; Baldini, M. T.; Mihm, M. C.; Cascinelli, N.

In: Melanoma Research, Vol. 6, No. 1, 1996, p. 63-69.

Research output: Contribution to journalArticle

Clemente, C, Belli, F, Mascheroni, L, Bufalino, R, Rao, S, Baldini, MT, Mihm, MC & Cascinelli, N 1996, 'Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients', Melanoma Research, vol. 6, no. 1, pp. 63-69.
Clemente, C. ; Belli, F. ; Mascheroni, L. ; Bufalino, R. ; Rao, S. ; Baldini, M. T. ; Mihm, M. C. ; Cascinelli, N. / Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. In: Melanoma Research. 1996 ; Vol. 6, No. 1. pp. 63-69.
@article{a233cd45fc934423b8ebfbbc76169598,
title = "Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients",
abstract = "Eight patients with cutaneous metastatic melanoma were submitted to high-dose intravenous thymopentin (TP5) treatment for 5 weeks: three patients received 1 g three times a week, three received 1 g daily and two received 2 g daily. Four out of eight patients presented a partial response of cutaneous lesions lasting for 1-7 months, and six remain alive with evidence of disease after a follow-up of 2-7 months. A remarkable histologic observation is the presence of tumour necrosis, which was seen as both single cells and large confluent areas. The majority of lymphold cells present in the tumour are CD45RO+ and CD4+. The CD4+ cells might play an important role in the anti-tumour immune local response by secreting cytokines and inducing apoptotic and necrotic cell death. This hypothesis seems to be confirmed by the presence of a high number of CD4+ cells around intratumoral vessels, while the presence of endovascular micro-thrombosis provides indirect evidence of cytokine activity. Cellular lysis may be produced by the activity of both CD8+ and CD4+ lymphoid cells. The role of TP5 may be an activation of CD4+ and CD8+ lymphold cells. Clinical and pathological data indicate that TP5 is able to produce consistent clinical and immunological effects in melanoma patients with cutaneous metastases.",
keywords = "Immunomodulator, Melanoma, Thymopentin, TIL, TP5",
author = "C. Clemente and F. Belli and L. Mascheroni and R. Bufalino and S. Rao and Baldini, {M. T.} and Mihm, {M. C.} and N. Cascinelli",
year = "1996",
language = "English",
volume = "6",
pages = "63--69",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients

AU - Clemente, C.

AU - Belli, F.

AU - Mascheroni, L.

AU - Bufalino, R.

AU - Rao, S.

AU - Baldini, M. T.

AU - Mihm, M. C.

AU - Cascinelli, N.

PY - 1996

Y1 - 1996

N2 - Eight patients with cutaneous metastatic melanoma were submitted to high-dose intravenous thymopentin (TP5) treatment for 5 weeks: three patients received 1 g three times a week, three received 1 g daily and two received 2 g daily. Four out of eight patients presented a partial response of cutaneous lesions lasting for 1-7 months, and six remain alive with evidence of disease after a follow-up of 2-7 months. A remarkable histologic observation is the presence of tumour necrosis, which was seen as both single cells and large confluent areas. The majority of lymphold cells present in the tumour are CD45RO+ and CD4+. The CD4+ cells might play an important role in the anti-tumour immune local response by secreting cytokines and inducing apoptotic and necrotic cell death. This hypothesis seems to be confirmed by the presence of a high number of CD4+ cells around intratumoral vessels, while the presence of endovascular micro-thrombosis provides indirect evidence of cytokine activity. Cellular lysis may be produced by the activity of both CD8+ and CD4+ lymphoid cells. The role of TP5 may be an activation of CD4+ and CD8+ lymphold cells. Clinical and pathological data indicate that TP5 is able to produce consistent clinical and immunological effects in melanoma patients with cutaneous metastases.

AB - Eight patients with cutaneous metastatic melanoma were submitted to high-dose intravenous thymopentin (TP5) treatment for 5 weeks: three patients received 1 g three times a week, three received 1 g daily and two received 2 g daily. Four out of eight patients presented a partial response of cutaneous lesions lasting for 1-7 months, and six remain alive with evidence of disease after a follow-up of 2-7 months. A remarkable histologic observation is the presence of tumour necrosis, which was seen as both single cells and large confluent areas. The majority of lymphold cells present in the tumour are CD45RO+ and CD4+. The CD4+ cells might play an important role in the anti-tumour immune local response by secreting cytokines and inducing apoptotic and necrotic cell death. This hypothesis seems to be confirmed by the presence of a high number of CD4+ cells around intratumoral vessels, while the presence of endovascular micro-thrombosis provides indirect evidence of cytokine activity. Cellular lysis may be produced by the activity of both CD8+ and CD4+ lymphoid cells. The role of TP5 may be an activation of CD4+ and CD8+ lymphold cells. Clinical and pathological data indicate that TP5 is able to produce consistent clinical and immunological effects in melanoma patients with cutaneous metastases.

KW - Immunomodulator

KW - Melanoma

KW - Thymopentin

KW - TIL

KW - TP5

UR - http://www.scopus.com/inward/record.url?scp=0030041050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030041050&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 63

EP - 69

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -